Hello Bio, Inc. 304 Wall St., Princeton, NJ 08540 USA

T. 609-683-7500 F. 609-228-4994

customercare-usa@m2stage.hellobio.com



DATASHEET

Recombinant mouse Midkine protein

Product overview

Name Recombinant mouse Midkine protein

Cat No HB6469 Species of origin mouse

Alternative names Recombinant Mouse Midkine, NEGF-2, Neurite Growth-Promoting Factor 2, MK, Neurite outgrowth-

promoting protein, Midgestation and kidney protein, Amphiregulin-associated protein, ARAP, Neurite

outgrowth-promoting factor 2, FLJ27379, Midkine, MK1, NEGF2.

Purity

Mouse Midkine recombinant protein Description

Biological Data

Application notes Fully biologically active when compared to standard. Determined by its ability to chemoattract human

neutrophils using a concentration range of 10-100 ng/ml corresponding to a specific activity of

10,000-100,000IU/mg.

Solubility & Handling

Solubility overview To make a stock solution, reconstitute in sterile 18MΩcm water at a concentration > 100µg/ml, which

can then be diluted to make a working solution

Handling • Solutions should be made in sterile deionized water (not less than 100 µg/ml). This solution can

then be further diluted with other aqueous solutions.

• Following reconstitution, solutions may be stored at 4°C and are useable for around 2-7 days

and for future use store at -18°C. • Freeze-thaw cycles should be prevented.

Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not

for human or veterinary use.

Chemical Data

UniProt ID P12025 Source E. Coli.

White lyophilized powder (sterile filtered & freeze-dried) **Appearance Formulation** Lyophilized from a 0.2µm filtered solution in PBS (pH 7.4)

References

Laminin is associated with the neurite outgrowth-promoting factors" found in conditioned media"

Lander AD et al (1985) Proc Natl Acad Sci U S A 82(7)

PubMedID 3856891

Astroglial neurotrophic and neurite-promoting factors

Muller HW et al (1995) Pharmacol Ther 65(1)

PubMedID 7716180

Midkine: a promising molecule for drug development to treat diseases of the central nervous system

Muramatsu T (2011) Curr Pharm Des 17(5) **PubMedID**21375488